Review of NICE Technology Appraisal Guidance No.251; Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia, and No.70; The clinical and cost effectiveness of imatinib for first line treatment of chronic myeloid leukaemia

Proposal to move the existing guidance to the static list

The planned date for review of TA251 was May 2014. 

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

Recommendations 1.1 and 1.3 of TA70 have already been updated by TA251 and TA241 respectively.  The remaining recommendations are included in this review proposal.

There is currently no available evidence that would lead to a change in the existing recommendations.  Consequently we propose that both TA251 and the remaining recommendations made in TA70 should move to the static list of technology appraisals.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.  Please see appendix A for a full list of the organisations we have contacted. 

August 2014

Attachments: